Eli Lilly and Company is to acquire Dermira Inc, a US medical dermatology company, for $1.1 billion in an all-cash transaction in order to expand its immunology pipeline. Dermira’s most advanced clinical programme, lebrikizumab, is a monoclonal antibody for moderate-to-severe atopic dermatitis. The company also has a marketed product for the topical treatment of primary axillary hyperhidrosis, a rare sweating disorder.
